PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.02%
Revenue growth at 75-90% of 3141.T's 5.95%. Bill Ackman would push for innovation or market expansion to catch up.
7.85%
Gross profit growth above 1.5x 3141.T's 3.95%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
14.12%
Positive EBIT growth while 3141.T is negative. John Neff might see a substantial edge in operational management.
30.87%
Positive operating income growth while 3141.T is negative. John Neff might view this as a competitive edge in operations.
8.00%
Positive net income growth while 3141.T is negative. John Neff might see a big relative performance advantage.
8.01%
Positive EPS growth while 3141.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
8.01%
Positive diluted EPS growth while 3141.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.00%
Share reduction while 3141.T is at 12.50%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3141.T is at 16.97%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.61%
10Y revenue/share CAGR under 50% of 3141.T's 26.25%. Michael Burry would suspect a lasting competitive disadvantage.
1.61%
5Y revenue/share CAGR under 50% of 3141.T's 26.25%. Michael Burry would suspect a significant competitive gap or product weakness.
-23.57%
Negative 3Y CAGR while 3141.T stands at 16.56%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-100.00%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-100.00%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
No Data
No Data available this quarter, please select a different quarter.
0.22%
Below 50% of 3141.T's 87.30%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
0.22%
Below 50% of 3141.T's 87.30%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-39.53%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.39%
Negative 3Y equity/share growth while 3141.T is at 63.85%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-100.00%
Cut dividends over 10 years while 3141.T stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-100.00%
Negative 5Y dividend/share CAGR while 3141.T stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
No Data
No Data available this quarter, please select a different quarter.
-99.58%
Firm’s AR is declining while 3141.T shows 20.09%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-1.78%
Inventory is declining while 3141.T stands at 11.88%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
6.99%
Asset growth at 50-75% of 3141.T's 13.98%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
4.08%
Positive BV/share change while 3141.T is negative. John Neff sees a clear edge over a competitor losing equity.
10.80%
We have some new debt while 3141.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
63.10%
SG&A growth well above 3141.T's 8.31%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.